Cytosurge, a leading global provider for precision single cell manipulation, is delighted to announce that together with the Laboratory of Biosensors and Bioelectronics (LBB) at the Swiss Federal Institute of Technology (ETH) in Zurich it has been awarded a prestigious project grant by the Swiss Innovation Agency Innosuisse.
Interest in organ-on-a-chip technologies has increased in recent years, particularly in the field of pharmacological testing. However, the current methods largely lack the capabilities of manipulating biological models made of spheroids, organoids, or single cells. Especially working with highly sensitive cells, such as stem cells (induced pluripotent stem cells; iPSCs) or neurons is challenging, thereby hindering their efficient use in such systems.
Cytosurge‘s FluidFM® OMNIUM system is designed for single cell research. Its proprietary FluidFM® technology combines force microscopy with microfluidics and enables gentle cell manipulation while preserving cell viability. The technology is especially suited for neurons, where maintaining the viability of manipulated cells is challenging. With its high precision, the FluidFM® OMNIUM can precisely place single neurons in pre-defined patterns to control their growth into complex systems.
Now the unique capabilities of Cytosurge’s FluidFM® OMNIUM system will be leveraged through the neuroscience expertise of LBB, ETH Zurich, led by Prof. Janos Vörös. The aim is to develop a method for autonomous recognition of viable neurons and their automatic repositioning into a defined pattern. Neuroscientists can then efficiently build highly defined complex model systems for neurodegenerative diseases starting from single neurons.
“This project addresses the most critical bottleneck of spheroid, organoid and single cell research,” stated Prof. Janos Vörös, Head of the Laboratory of Biosensors and Bioelectronics (LBB) at the Swiss Federal Institute of Technology (ETH). “In collaboration with Cytosurge, the automated handling of these tiny biological objects with unprecedented precision enables us to create extremely well-defined neuronal networks consisting of multiple cell types to drive neuroscience from the bottom-up – starting from a single cell.”
By advancing Cytosurge’s FluidFM® technology for the study of neuronal functioning at the single cell level, the partners have a shared vision to provide tools that can efficiently enable the realization of new organ-on-a-chip systems that could better mimic various neuropathies, such as Alzheimer’s, Parkinson’s, ALS and many more.
“There is a huge need for biologically relevant models in the neuroscience field to better understand how brains work and how we can tackle neurodegenerative diseases,” added Dr. Pascal Behr, CEO of Cytosurge. “From our interactions with the neuroscience community, we have realized that there is a great need in the research instrumentation market for solutions that allow researchers to go beyond what is currently possible in neuroscience. This project with Prof. Janos Vörös, funded by Innosuisse, enables us to further optimize and automate our FluidFM® technology to develop such neuronal network models even faster and with even higher precision. Our aim is to accelerate neuroscience research to find therapies that can improve the quality of life for patients with neurodegenerative diseases.”
Laboratory of Biosensors and Bioelectronics (LBB), ETH Zurich, Switzerland
We conduct interdisciplinary research at the interface between engineering, nanotechnology, materials science, medicine, and biology.
We apply our knowledge for developing new nanoscale tools and methods for biosensing, diagnostics, and interfacing biology. We also develop new biomedical devices using stretchable electronics.
Besides our application-oriented activities, we are also interested in answering basic research questions about how our brain processes and stores information using controlled neural networks that we analyze with machine learning.
For more information, visit www.lbb.ethz.ch.
Cytosurge, a Swiss-based global leader in precision single cell manipulation, was founded in 2009 by scientists at the Swiss Federal Institute of Technology (ETH Zurich).
The company develops, manufactures, and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology, designed for single cell research. This technology combines force microscopy with microfluidics and enables gentle cell manipulation while preserving cell viability and is especially suited for brain cells such as neurons. With its solutions, Cytosurge brings significant benefits to a wide range of life science applications.
Worldwide, more than 100 laboratories are already using FluidFM® systems, pushing conventional technological boundaries in CRISPR cell line development, mechanobiology, virology, single cell omics, neuroscience, and nanoprinting.
For more information, visit www.cytosurge.com.
Phone +41 43 544 87 00
Email [email protected]